Sanofi-aventis announced that the US Food and Drug Administration (FDA) approved Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil (TPF regimen), for induction therapy of locally advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) before patients undergo chemoradiotherapy and surgery.

The FDA based its approval on the results of the phase III randomized, open-label, international trial, TAX 324, which established the efficacy and safety of the Taxotere-based regimen in significantly improving survival.

Among patients treated with Taxotere-based therapy overall survival was significantly improved compared to patients receiving just cisplatin and 5-fluorouracil; the relative risk of death was 30 per cent lower. Patients treated with TPF had a longer median overall survival of 70.6 months vs 30.1 months for patients receiving PF only, representing a more than three year improvement in median OS for patients treated with TPF. The probability to survive three years was 62 per cent in the TPF arm compared to 48 per cent in the PF arm.

"The TAX 324 trial found that the addition of Taxotere to standard induction chemotherapy significantly improved patient survival, adding years to patients' lives," noted clinical investigator Marshall Posner, MD, medical director of the head and neck oncology Programme at Dana-Farber Cancer Institute in Boston. "The approval of Taxotere to be given in combination with other standard chemotherapy as the first step in a therapeutic sequence followed by chemoradiotherapy and surgery is a significant advancement in treatment for patients with locally advanced head and neck cancer".

All patients entering TAX 324 had tumours of the oropharynx, larynx, hypopharynx or oral cavity that either could not be removed, were considered potentially operable but unlikely to be cured with surgery, or could not be removed in order to preserve organ function. Participants in the trial had either stage III or IV SCCHN with no distant metastases.
Patients were treated every three weeks for three cycles with either TPF (Taxotere 75 mg/m2 plus cisplatin 100 mg/m2 and 5-fluorouracil 1000 mg/m2 a day for four days) or PF (intravenous cisplatin 100 mg/m2 followed by 5-fluorouracil 1000 mg/m2 a day for five days), the standard therapy. Both groups of patients were then given weekly chemotherapy (carboplatin) together with radiation therapy for seven weeks, followed by surgery for those patients identified as candidates.

The study was designed primarily to evaluate Overall Survival. Secondary endpoint included Progression-Free Survival, response rates, toxicity, quality of life and clinical benefits. Overall, the incidence of grade 3/4 toxicity was 65 per cent in the Taxotere arm (TPF) compared to 62 per cent in the group receiving cisplatin and fluorouracil (PF).

Head and neck cancer is a group of many related diseases that mostly begin in the cells that line the mucosal surfaces in the head and neck area such as the mouth, tongue, tonsils, throat and voicebox. The term encompasses cancers of the oral cavity, salivary glands, paranasal sinuses and nasal cavity, pharynx, larynx, and lymph nodes in the upper part of the neck.

"Head and neck cancer is particularly hard to treat and if not detected early has low survival rates," commented Nancy Leupold, survivor, president and founder of Support for People with Oral and Head and Neck Cancer (SPOHNC). "The availability of effective therapies that advance treatment and help patients live longer is very welcome news for the cancer community".

In the United States and in Europe Taxotere is approved to treat patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. It is also approved in Europe in combination with doxorubicin for patients who have received prior cytotoxic therapy for this condition and in combination with capecitabine after failure of cytotoxic therapy which would have included anthracycline.

In the adjuvant setting (post surgery) it is approved in the US and in Europe in combination with doxorubicin and cyclophosphamide (TAC regimen) for the treatment of patients with operable, nodepositive breast cancer. Finally, in Europe, Taxotere is approved in combination with trastuzumab for the treatment of patients with metastatic breast cancer- overexpressing HER2 receptor.